Comments
Roche's Avastin misses key data point in brain cancer study
18.11.2012. | ZURICH (Reuters) - Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the company said on Saturday....
